Last updated on March 2013

Phase I Study of Vasoactive Intestinal Peptide in Patients With Acute Respiratory Distress Syndrome and Sepsis


Brief description of study

OBJECTIVES: I. Determine the maximum tolerated dose of vasoactive intestinal peptide in patients with acute respiratory distress syndrome. II. Evaluate the safety and pharmacodynamic activity of this peptide in these patients.

Detailed Study Description

PROTOCOL OUTLINE: This is a dose escalation study. Patients receive vasoactive intestinal peptide (VIP) IV over either 6 or 12 hours. Cohorts of 3 patients each receive escalating doses of VIP over either 6 or 12 hours until the maximum tolerated dose is determined. Patients are followed for 30 days.

Clinical Study Identifier: NCT00004494

Contact Investigators or Research Sites near you

Start Over

Sami I. Said

Veterans Affairs Medical Center - Northport
Northport, NY United States
  Connect »

Sami I. Said

State University of New York Health Sciences Center - Stony Brook
Stony Brook, NY United States
  Connect »